CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


standard medical treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2706 Yin Hu Qing Wen Granula(low does) Wiki 1.00
drug2709 Yinhu Qingwen Granula Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Granula as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this adaptive, randomized,double-blind,controlled trial will evaluate the efficacy and safety of Yinhu Qingwen Granula in patients hospitalized with severe CoVID-19.

NCT04310865 COVID-19 Severe Pneumonia Chinese Medicine Drug: Yinhu Qingwen Granula Drug: Yin Hu Qing Wen Granula(low does) Other: standard medical treatment
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: changes in the ratio of PaO2 to FiO2 from baseline

Time: Day 10

Secondary Outcomes

Measure: PaO2

Time: up to 30 days

Measure: blood oxygen saturation (SpO2)

Time: up to 30 days

Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.

Measure: clinical status rating on the 7-point ordinal scale

Time: up to 30 days

Description: TTCI is defined as the time (in days) from initiation of study treatment (Yinhu Qingwen Granula or its low-dose granula) until a decline of two categories from status at randomisation on the 7-point ordinal scale of clinical status which ranges from 0 (death) to 6 (Not hospitalized, no limitations on activities).

Measure: Time to Clinical Improvement (TTCI)

Time: up to 30 days

Measure: Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use

Time: up to 30 days

Measure: Duration (hours) of invasive mechanical ventilation use

Time: up to 30 days

Measure: Duration (hours) of extracorporeal membrane oxygenation (ECMO) use

Time: up to 30 days

Measure: Duration (days) of Oxygen use

Time: up to 30 days

Measure: The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment

Time: Day 10

Measure: The counts/percentage of Lymphocyte

Time: up to 30 days

Measure: Time to hospital discharge with clinical recovery from the randomisation

Time: up to 30 days

Description: Critical status is defined as: 1) respiratory failure with the need of invasive mechanical ventilation; or 2) shock; or 3) other system organ failure with ICU admission.

Measure: The incidence of critical status conversion in 30 days

Time: up to 30 days

Measure: All-cause mortality within 30 days

Time: up to 30 days

Measure: Frequency of severe adverse drug events

Time: up to 30 days


Related HPO nodes (Using clinical trials)